Quantity of eligible patients: CDEC talked about the uncertainty in the quantity of people with reasonably intense to intense hemophilia B in Canada suitable for etranacogene dezaparvovec. Medical authorities consulted by CADTH indicated that some sufferers who're classified as obtaining mild or